바이오마커 시장 : 바이오마커 유래, 기술, 바이오마커 유형, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Biomarkers Market is projected to grow by USD 178.08 billion at a CAGR of 14.72% by 2032.

Biomarkers are measurable biological indicators used to detect disease, stratify patients, predict treatment response, monitor progression, and support drug safety. In precision medicine, they connect molecular diagnostics, companion diagnostics, liquid biopsy, pharmacogenomics, digital health, and clinical trial design.

Industry momentum is supported by verified trends in oncology, cardiovascular disease, neurology, immunology, infectious disease, and rare disease research, alongside expanding use of FDA-cleared and EMA-aligned diagnostic pathways, ClinicalTrials.gov biomarker-enriched studies, biobanks, and population genomics programs. Biomarkers are increasingly central to evidence-based care because they help translate molecular, cellular, imaging, and physiological signals into clinically actionable decisions.

Transformative Shifts in the Biomarkers Landscape

The biomarkers landscape is shifting from single-analyte testing toward integrated multi-omics that combines genomics, transcriptomics, proteomics, metabolomics, imaging, pathology, and real-world clinical data. Liquid biopsy, minimal residual disease testing, circulating tumor DNA, circulating tumor cells, and extracellular vesicle analysis are expanding noninvasive approaches, especially in oncology.

Regulatory expectations are also evolving. FDA companion diagnostic guidance, EU IVDR requirements, ICH clinical development standards, and good clinical laboratory practices are pushing industry toward stronger analytical validation, clinical validity, reproducibility, quality systems, and evidence generation across decentralized and multicenter studies. The shift is also visible in clinical trials, where biomarker-based patient enrichment, adaptive designs, and surrogate endpoint evaluation are becoming more prominent.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating biomarker discovery by identifying patterns across sequencing data, pathology images, radiology scans, electronic health records, wearable signals, and trial datasets. Machine learning supports patient enrichment, response prediction, digital biomarkers, adverse-event surveillance, target identification, and multi-omics feature selection.

The cumulative impact is significant but evidence dependent. Industry leaders must address algorithmic bias, model transparency, dataset provenance, privacy, cybersecurity, interoperability, and prospective clinical validation. Regulators increasingly expect AI-enabled biomarkers to demonstrate performance across representative populations and real clinical settings, particularly when algorithms influence diagnosis, treatment selection, clinical trial eligibility, or patient monitoring.

Key Regional Insights

North America remains a leading region for biomarker innovation, supported by FDA regulatory pathways, NIH-funded research, ClinicalTrials.gov activity, major cancer centers, accredited laboratory networks, and established reimbursement discussions. Europe benefits from EMA scientific advice, EU IVDR implementation, national genomic medicine initiatives, and strong biobank infrastructure, with cross-border research programs supporting harmonized evidence generation for molecular diagnostics and companion diagnostics.

Asia-Pacific is scaling rapidly through China, Japan, India, South Korea, and Australia, where genomics, oncology diagnostics, clinical research capacity, sequencing infrastructure, and digital health adoption continue to expand. Latin America shows growing adoption in Brazil and Mexico, particularly in oncology, infectious disease, and molecular pathology, while the Middle East is advancing national genomics, specialty care, and cancer screening initiatives. Africa is progressing through public health diagnostics, infectious disease surveillance, cancer control programs, and emerging genomics collaborations, although laboratory access, workforce capacity, and reimbursement remain uneven across countries.

Key Group Insights

The European Union is shaped by IVDR, cross-border research networks, health data initiatives, biobank interoperability, and cancer mission priorities that support evidence-based biomarker adoption. G7 economies generally lead in regulatory capacity, clinical trial infrastructure, payer scrutiny, genomic medicine implementation, and precision oncology deployment, while NATO members add relevance through health security, biosurveillance, military medicine, pandemic preparedness, and defense-related biomedical research.

BRICS countries are expanding biomarker research through large and genetically diverse populations, national genomics programs, public health priorities, growing clinical trial activity, and increasing life sciences investment. ASEAN is strengthening laboratory capacity, cancer diagnostics, infectious disease testing, and regional regulatory coordination, while GCC countries are investing in genomic medicine, specialty care, rare disease programs, oncology centers, and national health transformation strategies that elevate demand for validated biomarkers and companion diagnostics.

Key Country Insights

The United States leads through FDA oversight, NIH programs, major biopharma research activity, clinical trial density, molecular pathology infrastructure, and companion diagnostic commercialization. Canada supports genomics, oncology research, and real-world evidence programs, while Mexico and Brazil are expanding molecular diagnostics access across public and private systems, with oncology, infectious disease, and inherited disease testing gaining clinical relevance. The United Kingdom advances population genomics through NHS-linked initiatives, cancer research networks, and structured health data assets.

Germany, France, Italy, and Spain benefit from strong clinical research ecosystems, EU regulatory alignment, academic medical centers, national cancer strategies, and growing adoption of molecular tumor boards, while Russia maintains specialized biomedical capabilities and clinical research expertise in selected therapeutic areas. China, India, Japan, Australia, and South Korea are central to Asia-Pacific biomarker development, combining large patient populations, sequencing capacity, oncology innovation, pharmacogenomics research, digital health adoption, and regulatory frameworks that increasingly recognize precision medicine, companion diagnostics, and advanced in vitro diagnostics.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarkers with clear clinical utility, validated analytical performance, reproducible clinical validity, and payer-relevant outcomes. Early engagement with regulators, clinicians, laboratories, ethics committees, patient groups, and health technology assessment bodies improves alignment across companion diagnostic development, trial endpoints, labeling, reimbursement, and clinical adoption.

Organizations should invest in interoperable data infrastructure, representative cohorts, multi-omics integration, quality management, standardized sample handling, and prospective validation. Partnerships with academic medical centers, contract research organizations, diagnostic manufacturers, reference laboratories, and biobanks can reduce development risk and improve real-world adoption. Leaders should also build governance frameworks for AI-enabled biomarkers, digital biomarkers, data privacy, and post-market performance monitoring.

Research Methodology

The research approach combines secondary and primary intelligence from verified sources, including regulatory databases, clinical trial registries, peer-reviewed journals, public health agencies, patent literature, scientific congresses, health technology assessment publications, and national genomics or cancer programs.

Insights are triangulated across technology type, application area, end user, regulatory environment, clinical utility, evidence maturity, and geography. Validation emphasizes source credibility, recency, consistency, and relevance to biomarker discovery, development, analytical validation, clinical validation, companion diagnostics, liquid biopsy, digital biomarkers, multi-omics, and precision medicine adoption. The methodology excludes unverified assumptions and avoids market estimation, sizing, share, or forecasting.

Conclusion

Biomarkers are becoming foundational to precision medicine, enabling earlier diagnosis, better patient stratification, more efficient clinical trials, safer therapy selection, and improved disease monitoring. Progress is strongest where scientific validation, regulatory clarity, reimbursement logic, laboratory quality, and clinical workflow integration converge.

The next phase will be defined by multi-omics, AI-enabled discovery, liquid biopsy, digital biomarkers, real-world evidence, and broader use of companion diagnostics across therapeutic areas. Organizations that combine scientific rigor with scalable diagnostics, inclusive datasets, transparent validation, and demonstrable clinical utility will be best positioned for sustainable leadership in the evolving biomarkers landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biomarkers Market, by Biomarker Source

• 7.1. Blood
  • 7.1.1. Plasma
  • 7.1.2. Serum
• 7.2. Saliva
• 7.3. Tissue
• 7.4. Urine

8. Biomarkers Market, by Technology

• 8.1. Immunoassay
  • 8.1.1. Chemiluminescent Immunoassay
  • 8.1.2. Elisa
  • 8.1.3. Lateral Flow Assay
• 8.2. Mass Spectrometry
  • 8.2.1. Gas Chromatography Mass Spectrometry
  • 8.2.2. Liquid Chromatography Mass Spectrometry
  • 8.2.3. Matrix Assisted Laser Desorption Ionization Time Of Flight
• 8.3. Polymerase Chain Reaction
  • 8.3.1. Digital Polymerase Chain Reaction
  • 8.3.2. Quantitative Polymerase Chain Reaction
• 8.4. Sequencing
  • 8.4.1. Next Generation Sequencing
  • 8.4.2. Sanger Sequencing

9. Biomarkers Market, by Biomarker Type

• 9.1. Cellular Biomarkers
• 9.2. Genetic Biomarkers
  • 9.2.1. DNA Biomarkers
  • 9.2.2. RNA Biomarkers
• 9.3. Metabolomic Biomarkers
• 9.4. Protein Biomarkers

10. Biomarkers Market, by Application

• 10.1. Clinical Trials
• 10.2. Diagnostics
• 10.3. Drug Discovery
• 10.4. Personalized Medicine

11. Biomarkers Market, by End User

• 11.1. Academic And Research Institutes
• 11.2. Diagnostic Laboratories
• 11.3. Hospitals
• 11.4. Pharmaceutical Companies

12. Biomarkers Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Biomarkers Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Biomarkers Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Alto Neuroscience,Inc.
• 16.3. APIS Assay Technologies Limited
• 16.4. Augurex Life Sciences Corp
• 16.5. Bio-Rad Laboratories, Inc.
• 16.6. BioAgilytix
• 16.7. Biocrates Life Sciences AG
• 16.8. Biofourmis Inc.
• 16.9. Biognosys AG
• 16.10. BIOINFRA Life Science Inc.
• 16.11. BioStarks
• 16.12. BioVision Inc.
• 16.13. Charles River Laboratories, Inc.
• 16.14. Clarigent Corporation
• 16.15. EKF Diagnostics Holdings PLC
• 16.16. Elo Health, Inc.
• 16.17. F. Hoffmann-La Roche, Ltd.
• 16.18. Merck KgaA
• 16.19. Nightingale Health Plc
• 16.20. Owkin Inc.
• 16.21. Owlstone Medical Limited
• 16.22. PerkinElmer, Inc.
• 16.23. Personalis, Inc.
• 16.24. Proteomedix AG
• 16.25. QIAGEN GmbH
• 16.26. Renalytix PLC
• 16.27. Siemens Healthcare GmbH
• 16.28. Sino Biological Inc.
• 16.29. Thermo Fisher Scientific, Inc.
• 16.30. VivoSense, Inc.